Comparative Clinical Pathology

, Volume 29, Issue 1, pp 115–125 | Cite as

In silico molecular modeling and docking studies on the Leishmania mitochondrial iron transporter-1 (LMIT1)

  • Reza Pasandideh
  • Maryam DadmaneshEmail author
  • Saeed Khalili
  • Maysam Mard-Soltani
  • Khodayar Ghorban
Original Article


Leishmania mitochondrial iron transporter-1 (LMIT1) is a transmembrane protein required for normal mitochondrial structure and function. This protein is essential for the replication, survival, virulence, and the differentiation of promastigotes into infective amastigotes. Regarding the important role of LMIT1 in the iron-regulated process in Leishmania parasites, it can be considered as a promising target for structure-based drug design against leishmaniasis. In the present study, the three-dimensional (3D) structure of LMIT1 was determined by various in silico modeling approaches. The quality of the built models was evaluated using the different servers. The best model, which was predicted by Robetta, was selected for following analyses. Thereafter, the obtained model was successfully refined and used for determination of its probable inhibitors. Virtual screening of an approved compound library was employed to find the probable LMIT1 inhibitors. Ultimately, six molecules were found to inhibit the iron interaction with the LMIT1 in proper orientation and binding energy. The inhibitor candidates are shown to interact with functional residues of LMIT1. The achieved compounds could pave the way toward the development of new drugs against leishmaniasis in future studies.


Bioinformatics Leishmania amazonensis LMIT1 Modeling Robetta 



  1. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, Boer M, the WHO Leishmaniasis Control Team (2012) Leishmaniasis worldwide and global estimates of its incidence. PLoS One 7:e35671PubMedPubMedCentralGoogle Scholar
  2. Benkert P, Tosatto SC, Schomburg D (2008) QMEAN: a comprehensive scoring function for model quality assessment. Proteins: Struct, Funct Bioinf 71:261–277Google Scholar
  3. Benkert P, Biasini M, Schwede T (2010) Toward the estimation of the absolute quality of individual protein structure models. Bioinformatics 27:343–350PubMedPubMedCentralGoogle Scholar
  4. Bezerra IPS, Abib MA, Rossi-Bergmann B (2018) Intranasal but not subcutaneous vaccination with LaAg allows rapid expansion of protective immunity against cutaneous leishmaniasis. Vaccine 36:2480–2486Google Scholar
  5. Bhattacharya D, Cheng J (2013) i3Drefine software for protein 3D structure refinement and its assessment in CASP10. PLoS One 8:e69648PubMedPubMedCentralGoogle Scholar
  6. Brezovsky J, Chovancova E, Gora A, Pavelka A, Biedermannova L, Damborsky J (2013) Software tools for identification, visualization and analysis of protein tunnels and channels. Biotechnol Adv 31:38–49PubMedGoogle Scholar
  7. Carugo O, Djinović-Carugo K (2013) Half a century of Ramachandran plots. Acta Crystallogr Sect D 69:1333–1341Google Scholar
  8. Chawla B, Madhubala R (2010) Drug targets in Leishmania. J Parasit Dis 34:1–13PubMedPubMedCentralGoogle Scholar
  9. Das BB, Sengupta T, Ganguly A, Majumder HK (2006) Topoisomerases of kinetoplastid parasites: why so fascinating? Mol Microbiol 62:917–927PubMedGoogle Scholar
  10. dos Santos IB et al (2018) Leishmanicidal and immunomodulatory activities of the Palladacycle complex DPPE 1.1, a potential candidate for treatment of cutaneous Leishmaniasis. Front Microbiol 9:1–9Google Scholar
  11. Durrant JD, McCammon JA (2011) Molecular dynamics simulations and drug discovery. BMC Biol 9:1–9Google Scholar
  12. Fidalgo LM, Gille L (2011) Mitochondria and trypanosomatids: targets and drugs. Pharm Res 28:2758–2770PubMedGoogle Scholar
  13. Floudas C, Fung H, McAllister S, Mönnigmann M, Rajgaria R (2006) Advances in protein structure prediction and de novo protein design: a review. Chem Eng Sci 61:966–988Google Scholar
  14. Geourjon C, Deleage G (1995) SOPMA: significant improvements in protein secondary structure prediction by consensus prediction from multiple alignments. Bioinformatics 11:681–684Google Scholar
  15. Hajilooi M, Sardarian K, Dadmanesh M, Matini M, Lotfi P, Bazmani A, Tabatabaiefar MA, Arababadi MK, Momeni M (2013) Is the IL-10− 819 polymorphism associated with visceral Leishmaniasis? Inflammation 36:1513–1518PubMedGoogle Scholar
  16. Hopkins AL, Groom CR (2002) The druggable genome. Nat Rev Drug Discov 1:727–730PubMedGoogle Scholar
  17. Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14:33–38PubMedGoogle Scholar
  18. Kar S, Roy K (2013) How far can virtual screening take us in drug discovery? Expert Opin Drug Discov 8:245–261PubMedGoogle Scholar
  19. Keyvani H, Ahmadi NA, Ranjbar MM, Kachooei SA, Ghorban K, Dadmanesh M (2016) Immunoinformatics study of gp120 of human immunodeficiency virus type 1 subtype CRF35_AD isolated from Iranian patients. Arch Clin Infect Dis 11:1–9Google Scholar
  20. Khalili S, Rahbar MR, Dezfulian MH, Jahangiri A (2015) In silico analyses of Wilms′ tumor protein to designing a novel multi-epitope DNA vaccine against cancer. J Theor Biol 379:66–78PubMedGoogle Scholar
  21. Khalili S, Mohammadpour H, BAROUGH MS, Kokhaei P (2016) ILP-2 modeling and virtual screening of an FDA-approved library: a possible anticancer therapy. Turk J Med Sci 46:1135–1143PubMedGoogle Scholar
  22. Khalili S, Jahangiri A, Hashemi ZS, Khalesi B, Mard-Soltani M, Amani J (2017a) Structural pierce into molecular mechanism underlying Clostridium perfringens epsilon toxin function. Toxicon 127:90–99PubMedGoogle Scholar
  23. Khalili S, Rasaee M, Bamdad T (2017b) 3D structure of DKK1 indicates its involvement in both canonical and non-canonical Wnt pathways. Mol Biol 51:155–166Google Scholar
  24. Khalili S, Zakeri A, Hashemi ZS, Masoumikarimi M, Manesh MRR, Shariatifar N, Sani MJ (2017c) Structural analyses of the interactions between the thyme active ingredients and human serum albumin. Turk J Biochem 42:459–467Google Scholar
  25. Kim DE, Chivian D, Baker D (2004) Protein structure prediction and analysis using the Robetta server. Nucleic Acids Res 32:W526–W531PubMedPubMedCentralGoogle Scholar
  26. Kopp J, Schwede T (2004) Automated protein structure homology modeling: a progress report. Pharmacogenomics 5:405–416PubMedGoogle Scholar
  27. Lacapere J-J, Pebay-Peyroula E, Neumann J-M, Etchebest C (2007) Determining membrane protein structures: still a challenge! Trends Biochem Sci 32:259–270PubMedGoogle Scholar
  28. Liang J, Naveed H, Jimenez-Morales D, Adamian L, Lin M (2012) Computational studies of membrane proteins: models and predictions for biological understanding. Biochim Biophys Acta Biomembr 1818:927–941Google Scholar
  29. Lin H-N, Sung T-Y, Ho S-Y, Hsu W-L (2010) Improving protein secondary structure prediction based on short subsequences with local structure similarity. BMC Genomics 4:1–14Google Scholar
  30. Magaraci F, Jimenez, Rodrigues C, Rodrigues JCF, Braga MV, Yardley V, de Luca-Fradley K, Croft SL, de Souza W, Ruiz-Perez LM, Urbina J, Pacanowska DG, Gilbert IH (2003) Azasterols as inhibitors of sterol 24-methyltransferase in Leishmania species and Trypanosoma c ruzi. J Med Chem 46:4714–4727PubMedGoogle Scholar
  31. Martinez PA, Petersen CA (2014) Chronic infection by Leishmania amazonensis mediated through MAPK ERK mechanisms. Immunol Res 59:153–165PubMedPubMedCentralGoogle Scholar
  32. Martínez-García M et al (2016) LmABCB3, an atypical mitochondrial ABC transporter essential for Leishmania major virulence, acts in heme and cytosolic iron/sulfur clusters biogenesis. Parasit Vectors 9:1–17Google Scholar
  33. Mather MW, Henry KW, Vaidya AB (2007) Mitochondrial drug targets in apicomplexan parasites. Curr Drug Targets 8:49–60PubMedGoogle Scholar
  34. McGuffin LJ, Bryson K, Jones DT (2000) The PSIPRED protein structure prediction server. Bioinformatics 16:404–405PubMedGoogle Scholar
  35. Mehta A, Shaha C (2004) Apoptotic death in Leishmania donovani promastigotes in response to respiratory chain inhibition complex II inhibition results in increased Pentamidine cytotoxicity. J Biol Chem 279:11798–11813PubMedGoogle Scholar
  36. Mittra B, Cortez M, Haydock A, Ramasamy G, Myler PJ, Andrews NW (2013) Iron uptake controls the generation of Leishmania infective forms through regulation of ROS levels. J Exp Med 210:401–416PubMedPubMedCentralGoogle Scholar
  37. Mittra B, Laranjeira-Silva MF, de Menezes JPB, Jensen J, Michailowsky V, Andrews NW (2016) A trypanosomatid iron transporter that regulates mitochondrial function is required for Leishmania amazonensis virulence. PLoS Pathog 12:e1005340PubMedPubMedCentralGoogle Scholar
  38. Mittra B, Laranjeira-Silva MF, Miguel DC, de Menezes JPB, Andrews NW (2017) The iron-dependent mitochondrial superoxide dismutase SODA promotes Leishmania virulence. J Biol Chem 21:1–32Google Scholar
  39. Mohammadpour H, Khalili S, Hashemi ZS (2015) Kremen is beyond a subsidiary co-receptor of Wnt signaling: an in silico validation. Turk J Biol 39:501–510Google Scholar
  40. Molegro A (2011) MVD 5.0 Molegro virtual Docker DK-8000 Aarhus C, DenmarkGoogle Scholar
  41. Monzote L, Gille L (2010) Mitochondria as a promising antiparasitic target. Curr Clin Pharmacol 5:55–66PubMedGoogle Scholar
  42. Nagle AS, Khare S, Kumar AB, Supek F, Buchynskyy A, Mathison CJN, Chennamaneni NK, Pendem N, Buckner FS, Gelb MH, Molteni V (2014) Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis. Chem Rev 114:11305–11347PubMedPubMedCentralGoogle Scholar
  43. Niu Q, Li S, Chen D, Chen Q, Chen J (2016) Iron acquisition in Leishmania and its crucial role in infection. Parasitology 143:1347–1357PubMedGoogle Scholar
  44. de Oliveira AM, Custódio FB, Donnici CL, Montanari CA (2003) QSAR and molecular modelling studies on B-DNA recognition of minor groove binders European. J Med Chem 38:141–155Google Scholar
  45. Pavelka A, Chovancova E, Damborsky J (2009) HotSpot wizard: a web server for identification of hot spots in protein engineering. Nucleic Acids Res 37:W376–W383PubMedPubMedCentralGoogle Scholar
  46. Pavlova A, Hwang H, Lundquist K, Balusek C, Gumbart JC (2016) Living on the edge: simulations of bacterial outer-membrane proteins. Biochim Biophys Acta Biomembr 1858:1753–1759Google Scholar
  47. Payandeh Z, Rajabibazl M, Mortazavi Y, Rahimpour A (2017) In silico analysis for determination and validation of human CD20 antigen 3D structure. Int J Pept Res Ther 25:1–13Google Scholar
  48. Ranjbar MM, Nayeb Ali A, Ghorban K, Ghalyanchi Langeroudi A, Dadmanesh M, Amini H-R, Sedighi Moghaddam B (2015) Immnoinformatics: novel view in understanding of immune system function, databases and prediction of immunogenic epitopes. Koomesh 17:18–26Google Scholar
  49. Reguera RM et al (2019) Current and promising novel drug candidates against visceral leishmaniasis. Pure Appl Chem:1–20Google Scholar
  50. Roberts C, McLeod R, Rice D, Ginger M, Chance M, Goad L (2003) Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. Mol Biochem Parasitol 126:129–142PubMedGoogle Scholar
  51. Robinson AJ, Kunji ER (2006) Mitochondrial carriers in the cytoplasmic state have a common substrate binding site. Proc Natl Acad Sci 103:2617–2622PubMedGoogle Scholar
  52. Roy A, Kucukural A, Zhang Y (2010) I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc 5:725–738PubMedPubMedCentralGoogle Scholar
  53. Sarkar A, Khan YA, Laranjeira-Silva MF, Andrews NW, Mittra B (2018) Quantification of intracellular growth inside macrophages is a fast and reliable method for assessing the virulence of Leishmania parasites. J Vis Exp 133:e57486Google Scholar
  54. Satheesh KS, Gokulasuriyan RK, Ghosh M (2014) Comparative in-silico genome analysis of Leishmania (Leishmania) donovani: a step towards its species specificity. Meta Gene 2:782–798Google Scholar
  55. Schmidt T, Bergner A, Schwede T (2014) Modelling three-dimensional protein structures for applications in drug design. Drug Discov Today 19:890–897PubMedGoogle Scholar
  56. Sen N, Majumder HK (2008) Mitochondrion of protozoan parasite emerges as potent therapeutic target: exciting drugs are on the horizon. Curr Pharm Des 14:839–846PubMedGoogle Scholar
  57. Shaddel M, Oormazdi H, Akhlaghi L, Kazemi B, Bandehpour M (2008) Cloning of Leishmania major P4 gene. Yakhteh Med J 10:201–204Google Scholar
  58. Shaddel M, Sharifi I, Karvar M, Keyhani A, Baziar Z (2018) Cryotherapy of cutaneous leishmaniasis caused by Leishmania major in BALB/c mice: a comparative experimental study. J Vector Borne Dis 55:42–46PubMedGoogle Scholar
  59. Shakya N, Bajpai P, Gupta S (2011) Therapeutic switching in Leishmania chemotherapy: a distinct approach towards unsatisfied treatment needs. J Parasit Dis 35:104–112PubMedPubMedCentralGoogle Scholar
  60. Silva LA, Vinaud MC, Castro AM, Cravo PVL, Bezerra JCB (2015) In silico search of energy metabolism inhibitors for alternative leishmaniasis treatments. Biomed Res Int 2015:1–6Google Scholar
  61. Suthar N, Goyal A, Dubey VK (2009) Identification of potential drug targets of Leishmania infantum by in-silico genome analysis. Lett Drug Des Discov 6:620–622Google Scholar
  62. Suzuki E, Tanaka AK, Toledo MS, Levery SB, Straus AH, Takahashi HK (2008) Trypanosomatid and fungal glycolipids and sphingolipids as infectivity factors and potential targets for development of new therapeutic strategies. Biochim Biophys Acta Gen Subj 1780:362–369Google Scholar
  63. Teng Y, Ding Y, Zhang M, Chen X, Wang X, Yu H, Liu C, Lv H, Zhang R (2018) Genome-wide haplotype association study identifies risk genes for non-small cell lung cancer. J Theor Biol 456:84–90PubMedGoogle Scholar
  64. Tian W, Chen C, Lei X, Zhao J, Liang J (2018) CASTp 3.0: computed atlas of surface topography of proteins. Nucleic Acids Res 46:W363–W367PubMedPubMedCentralGoogle Scholar
  65. Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31:455–461PubMedPubMedCentralGoogle Scholar
  66. Vidhya VM, Dubey VK, Ponnuraj K (2018) Identification of two natural compound inhibitors of Leishmania donovani spermidine synthase (SpdS) through molecular docking and dynamic studies. J Biomol Struct Dyn 36:2678–2693Google Scholar
  67. Viklund H, Elofsson A (2008) OCTOPUS: improving topology prediction by two-track ANN-based preference scores and an extended topological grammar. Bioinformatics 24:1662–1668PubMedGoogle Scholar
  68. Wiederstein M, Sippl MJ (2007) ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res 35:W407–W410PubMedPubMedCentralGoogle Scholar
  69. Wu S, Zhang Y (2008) MUSTER: improving protein sequence profile–profile alignments by using multiple sources of structure information. Proteins: Struct, Funct Bioinf 72:547–556Google Scholar
  70. Xun S, Jiang F, Wu Y-D (2015) Significant refinement of protein structure models using a residue-specific force field. J Chem Theory Comput 11:1949–1956PubMedGoogle Scholar
  71. Zaidi A, Singh KP, Ali V (2017) Leishmania and its quest for iron: an update and overview. Mol Biochem Parasitol 211:15–25PubMedGoogle Scholar

Copyright information

© Springer-Verlag London Ltd., part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Immunology, School of MedicineAja University of Medical SciencesTehranIran
  2. 2.Department of Infectious Diseases, School of MedicineAja University of Medical SciencesTehranIran
  3. 3.Infectious Diseases Research CenterAja University of Medical SciencesTehranIran
  4. 4.Department of Biology SciencesShahid Rajaee Teacher Training UniversityTehranIran
  5. 5.Department of Clinical Biochemistry, Faculty of Medical SciencesDezful University of Medical SciencesDezfulIran

Personalised recommendations